Genitourinary Cancer

An expert panel and focus groups in Michigan created Guidelines for the Primary Care Management of Prostate Cancer Post-Treatment Sequelae in 2009 and published an update in July 2014.

Genetics may be to blame for an increase in the number of young men diagnosed with prostate cancer, researchers say.

Rick Bulifant shares his bladder cancer story

It happens all the time. A man gets older, but he doesn't think he needs to be checked for prostate cancer. Even if his father or grandfather had prostate cancer, he feels fine, and does not see the need for yearly physical exams. However, the reality is that 1 in 7 American men will be diagnosed with prostate cancer at some point in his lifetime.

Pamela Devine, RN, clinical nurse specialist, Philadelphia Veterans Administration Medical Center, discusses some of the psychosocial issues that men face when they are receiving treatment for their prostate cancer.

Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists and oncology practitioners in collaboration with primary care physicians.

The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization funding and accelerating prostate cancer research.

Vanna Dest, MSN, APRN-BC, AOCN, Oncology Nurse Practitioner/Manager, Oncology APP, Smilow Cancer Hospital, discusses the risk factors of prostate cancer.

The American Cancer Society has released new Prostate Cancer Survivorship Care guidelines that outline post treatment clinical follow-up care for the myriad of long-term and late effects.

Despite evidence supporting its efficacy, chemotherapy is not routinely administered to patients with muscle-invasive bladder cancer (MIBC)

Prednisone, when used in concert with other therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC), does not raise the risk for severe toxicities, nor does it affect overall survival (OS)

Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.

Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

Donna L. Berry, PhD, RN, AOCN, FAAN, Director, Phyllis F. Cantor Center for Research in Nursing & Patient Care Services, Dana-Farber Cancer Institute, Associate Professor, Department of Medicine, Harvard Medical School, discusses decision support for men with localized prostate cancer.

The FDA's approval in 2010 of sipuleucel-T (Provenge) marked a milestone in the treatment of men with advanced prostate cancer and ushered in an exciting new immunotherapeutic treatment approach.

Immunotherapy has become an increasingly appealing therapeutic strategy for patients with cancer, with many late-stage clinical trials demonstrating overall survival (OS) advantages in melanoma and castration-resistant prostate cancer.

Men who experience hot flashes because they are undergoing androgendeprivation therapy for prostate cancer are not significantly helped by two treatments that alleviate the same symptom in menopausal women, the results of a study show.

Donna L. Berry, PhD, RN, AOCN, FAAN, from the Dana-Farber Cancer Institute and Harvard Medical School, discusses improving treatment decision support systems for minority men with localized prostate cancer.

The American Cancer Society estimates that in 2013, 142,820 individuals in the United States will be diagnosed with colorectal cancer and 72,570 with bladder cancer

Frank delaRama, RN, MS, AOCNS®, from the Palo Alto Medical Foundation, explains the role of oncology nurse navigators in providing relevant information to men with prostate cancer.

Information is key, as patients with early-stage prostate cancer typically choose among three standard treatment options: watchful waiting/active surveillance, surgery, and radiation.

A research team has discovered 12 genetic markers associated with the development of erectile dysfunction in prostate cancer patients treated with radiation.

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

The USPSTF releases its new recommendations for public comment.

Donna Berry on the Challenges Patients With Prostate Cancer Face